Parcom Capital acquires Viroclinics Biosciences

Parcom Capital has acquired clinical research organisation Viroclinics Biosciences – which tests around 90 percent of all anti-influenza medications developed worldwide.

The acquisition will give Viroclinics the opportunity to expand its fields of expertise and its portfolio of services. 

 Bob van Gemen, CEO Viroclinics Biosciences, is pleased with the acquisition by Parcom Capital.  “Our main focus at the moment is the research and treatment of respiratory viruses. We would like to broaden our portfolio, especially in the area of other viral targets, such as hepatitis, polio and RSV.

 “For instance, we are very closely involved in a project that is on the verge of eradicating the polio virus for good. In Parcom Capital, we have found a new, solid partner who will enable us to realise even more of our ambitious targets. In the coming years, we will enter a new phase as a company and we have major growth ambitions.” 

[Photography: Marieke de Lorijn/Viroclinics Biosciences ] 

Viroclinics was founded in 2001 specialising in testing new vaccines and drugs in the clinical trial stages prior to their market launch. It conducts virology testing for some of the world’s top biopharmaceutical companies.

 As a result of the sale, Viroclinics is now fully owned by mid-market private equity fund Parcom Capital and Management. “We see Viroclinics as a valuable addition to our portfolio,” says Parcom Capital partner Piet-Hein de Jager.

Gilde Healthcare Service is the selling party and was advised in the acquisition process by William Blair. Parcom was advised by PricewaterhouseCoopers. The acquisition has no consequences for the employees of Viroclinics. The parties decline to publish any financial details.